Newton001: Biomarkers of treatment naive psychosis.
Newton001: Biomarkers of treatment naive psychosis.
批准号:
MR/M026337/1
负责人:
Gerome Breen
金额:
$5.5万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2015
资助国家:
英国
项目状态:
已结题
起止时间:
2015 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The First Episode of Psychosis is perhaps the most important stage of schizophrenia, unless effective treatment is established during this phase many patients develop an unfavourable clinical outcome. If we can understand the biological markers associated with FEP and subsequent response to treatment, we maybe able to develop ways of predicting which treatment patients will respond best to. However, to understand this we need to examine samples from patients before they undergo drug treatment, as otherwise it is unclear what changes are due to the disorder/episode and what are due to the prescribed medication. We have collected blood samples (RNA, DNA and serum) from psychosis patients who are treatment naïve (before they received drug treatment for the disorder), and who have been followed for 8 weeks (N=80) and one year (N=30) after drug treatment. This group of patients is unique and being able to study biomarkers unaffected by the drugs given as treatments may allow us greater understanding of the causes and potential underlying risks for psychosis.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Blood gene expression changes after Risperidone treatment in an antipsychotic-naïve cohort of first episode of psychosis patients.
在初次接受抗精神病药物治疗的首次精神病患者队列中,利培酮治疗后血液基因表达发生变化。
DOI:
10.1016/j.schres.2020.03.033
发表时间:
2020
期刊:
Schizophrenia research
影响因子:
4.5
作者:
[Xavier G]
通讯作者:
Xavier G
Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
抗精神病药的症状和治疗反应分析的多基因风险评分分析精神病队列的抗精神病药。
DOI:
10.1038/s41398-018-0230-7
发表时间:
2018-08-31
期刊:
Translational psychiatry
影响因子:
6.8
作者:
[Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, Gouvea E, Lee SH, Moretti P, Curtis C, Patel H, Newhouse S, Carvalho CM, Gadelha A, Cordeiro Q, Bressan RA, Belangero SI, Breen G]
通讯作者:
Breen G
Eating Disorders Clinical Research Network
-
批准号:MR/X030539/1
-
项目类别:Research Grant
-
资助金额:$152.15万
-
财政年份:2023
-
负责人:Gerome Breen
-
依托单位:
国内基金
海外基金
基于自主研发的代谢型PCR芯片和代谢组学筛选的biomarkers在非霍奇金淋巴瘤个体化诊疗中的应用
-
批准号:81602609
-
项目类别:青年科学基金项目
-
资助金额:17.0万元
-
批准年份:2016
-
负责人:刘晓霞
-
依托单位:
趋势决定进展:动态对比软骨细胞空间结构模式与biomarkers变动趋势在OA防控中的潜在作用研究
-
批准号:81573245
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2015
-
负责人:张军锋
-
依托单位:
抗冻干胁迫的保加利亚乳杆菌糖代谢关键biomarkers识别及其作用机制
-
批准号:31201397
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2012
-
负责人:李春
-
依托单位: